Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 [lapatinib; Tyverb; GlaxoSmithKline] and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer.

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 [lapatinib; Tyverb; GlaxoSmithKline] and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GSK

    • Most Recent Events

    • 25 Jan 2016 Results of pooled analysis (n=1902) from this and two other trials (see profile 1409 and 2335) published in the Journal of Clinical Oncology
    • 03 Jun 2014 Results (meta-analysis) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 11 May 2010 Actual patient number changed from 399 to 408 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top